Brief: Belite Bio Says Lead Pipeline, Tinlarebant Granted Sakigake Designation By Ministry Of Health, Labour & Welfare In Japan (MHLW) For Treatment Of STGD1.
12/06/2024 07:57
June 12 (Reuters) - Belite Bio Inc BLTE.O :
* BELITE BIO RECEIVES SAKIGAKE (PIONEER DRUG) DESIGNATION OF
TINLAREBANT FOR STARGARDT DISEASE IN JAPAN
* BELITE: LEAD PIPELINE, TINLAREBANT, BEEN GRANTED SAKIGAKE
DESIGNATION BY MINISTRY OF HEALTH, LABOUR & WELFARE IN JAPAN
(MHLW) FOR TREATMENT OF STGD1.
Source text for Eikon: ID:nGNX1z0dHp
Further company coverage: BLTE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Belite Bio
See all newsBrief: Belite Bio Announces Uplisting To The Nasdaq Global Select Market
Brief: Belite Bio Announces Multi-Market Submission Of Marketing Authorization Applications Via The Access Consortium Pathway For Tinlarebant For The Treatment Of Stargardt Disease Type 1
Brief: Belite Bio Announces Submission Of New Drug Application To The Ministry Of Health, Labour, And Welfare In Japan Under The Sakigake Designation System For Tinlarebant For The Treatment Of Stargardt Disease Type 1
Belite Bio, Inc reports results for the quarter ended June 30 - Earnings Summary
Belite Bio Q2 net loss widens on higher expenses